An antibody single-domain phage display library of a native heavy chain variable region: Isolation of functional single-domain VH molecules with a unique interface

Journal of Molecular Biology

Volumn 290, Issue 3, 1999, Pages 685-698

  Reiter, Yoram ^a,b   Schuck, Peter ^c   Boyd, Lisa F ^d   Plaksin, Daniel ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Peptor Ltd   (Israel)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibody; Inclusion bodies; Phage display; Single domain; VH

Indexed keywords

ANTIBODY; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; CLONE; DRUG DESIGN; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN ISOLATION; PROTEIN PURIFICATION; RANDOMIZATION;

UNIDENTIFIED BACTERIOPHAGE;

EID: 0032763794     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.2923     Document Type: Article

References (48)

1. Adams G. P. Improving the tumor specificity and retention of antibody-based molecules. In Vivo. 12:1998;11-22.
2. Adams G. P., Schier R., McCall A. M., Crauford R. S., Wolf E. J., Weiner L. M., Marks J. D. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Brit. J. Cancer. 77:1998;1405-1412.
3. Adey N. B., Mataragnon A. H., Rider J. E., Carter J. M., Kay B. K. Characterization of phage that bind plastic from phage-displayed random peptide libraries. Gene. 156:1995;27-31.
4. Almog O., Benhar I., Vasmatzis G., Tordova M., Lee B., Pastan I., Gililand G. The crystal structure of the disulfide-stabilized Fv of anti-cancer antibody B1: Conformational influence of an engineered disulfide bond. Proteins: Struct. Funct. Genet. 31:1998;128-138.
5. Barbas C. F. Synthetic human antibodies. Nature Med. 1:1995;837-839.
6. Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M. Single-chain antigen binding proteins. Science. 242:1988;423-426.
7. Brumfeld V., Werber M. Studies of fibronectin and its domains. II. Secondary structure and spatial configuration of fibronectin and its domains. Arch. Biochem. Biophys. 302:1993;134-143.
8. Buchner J., Pastan I., Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem. 205:1992;263-270.
9. Chen Y., Stollar D. DNA binding by the VH domain of anti- Z -DNA antibody and its modulation by association of the VL domain. J. Immunol. 162:1999;4663-46700.
10. Chothia C., Lesk A. Canonical structures of the hypervariable regions of immunoglobulins. J. Mol. Biol. 196:1987;904-917.
11. Chothia C., Novotny J., Bruccoleri R., Karplus M. Domain association in immunoglobulin molecules. The packing of variable domains. J. Mol. Biol. 186:1985;651-663.
12. Chowdhury P. S., Viner J. L., Beers R., Pastan I. Isolation of a high affinity stable scFv specific for mesothelin from DNA immunized mice by phage display and construction of a recombinant immunotoxin with antitumor activity. Proc. Natl Acad. Sci. USA. 95:1998;669-674.
13. Colcher D., Bird R., Roselli M., Hardman K. D., Johnson S., Pope S., Dodd S. W., Pantolianio M. W., Milenic D., Schlom J. In vivo tumor targeting of a recombinant single-chain antigen binding protein. J. Natl Cancer Inst. 82:1990;1191-1197.
14. Corr M., Slanetz A. E., Boyd L. F., Jelonek M. T., Khilko S., Al Ramadi B. K., Kim Y. S., Maher S. E., Bothwell A. L., Margulies D. H. T cell receptor MHC class I peptide interactions: affinity, kinetics, and specificity. Science. 265:1994;946-949.
15. Davies J., Riechmann L. Antibody VH domains as small recognition units. Biotechnology. 13:1995;475-479.
16. Davies J., Riechmann L. Affinity improvement of single antibody VH domains. Residues in all three hyprevariable regions affect antigen binding. Immunotechnology. 2:1996;169-179.
17. Ghahroudi M. A., Desmyter A., Wyns L., Hamers R., Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Letters. 414:1997;521-526.
18. Glockshuber R., Malia M., Pfitzinger I., Pluckthun A. A comparision of strategies to stabilize immunoglobulin Fv fragments. Biochemistry. 29:1990;1362-1376.
19. Griffiths A. D., Williams C. S., Hartley O., Tomlinson I. M., Waterhouse P., Crosby W. L., Konterman R. E., Lones P. T., Low N. M., Allison T. J., Prospero T. D., Hoogenboom H., Nissim A., Cox P. L., Harrison J. L. et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245-3260.
20. Haard H., Henderikx P., Hoogenboom H. R. Creating and engineering human antibodies for immunotherapy. Advan. Drug Del. Rev. 31:1998;5-31.
21. Hoogenboom H. R., Bruine A. P., Hufton S. E., Hoet R. M., Arends J., Roovers R. C. Antibody phage display technology and its applications. Immunotechnology. 4:1998;1-20.
22. Huston J. S., Levinson D., Mudghett-Hunter M., Tai M. S., Novotny J., Margolies M. N. Protein enginnering of antibody binding sites: recovery of specific activity in an anti dogoxigenin single-chain Fv analogue produced in Eschericia coli. Proc. Natl Acad. Sci. USA. 85:1988;5879-5883.
23. Kabat E., Wu T. T., Perry H. M., Gottesman K. S., Foeller C. Sequences of proteins of immunological interest, publication no. 91-3242. 1991;US Public Health ServicesNIH, Bethesda.
24. HER2antibody Fab fragments. Biochemistry. 31:1992;5434-5441.
25. Kortt A. A., Guthrie R. E., Hinds M. G., Power B. E., Ivancic N., Caldwell B. J., Gruen L. C., Norton R. S., Hudson P. J. Solution properties of Escherichia coli -expressed VH domain of anti-neuraminidase antibody NC41. J. Protein Chem. 14:1995;167-178.
26. Lauwereys M., Ghahroudi M. A., Desmyter A., Kinne J., Holzer W., DeGenst E., Wyns L., Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 17:1998;3512-3520.
27. Lilie H., Jaenicke R., Buchner J. Characterization of a quaternary-structure folding intermediate of an antibody Fab-fragment. Protein Sci. 4:1995a;917-924.
28. Lilie H. R., Rudolf R., Buchner J. Association of antibody chains at different stages of folding: prolyl isomerization occurs after formation of quarternary structure. J. Mol. Biol. 248:1995b;190-201.
29. Lorimer I. A., Hafkemeyer A., Beers R. A., Pegram C., Bigner D. D., Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc. Natl Acad. Sci. USA. 93:1996;14815-14820.
30. Martin F., Volpari C., Steinkuhler C., Dimasi N., Brunetti M., Biasiol G., Altamura S., Cortese R., De Francesco R., Sollazzo M. Affinity selection of a camelized VH domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. 10:1997;607-614.
31. Muyldermans S., Atarhouch T., Saldanha J., Barbosa J. A., Hamers R. Sequence and structure of VH domain from naturally occuring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 7:1994;1129-1135.
32. Ozato K., Mayer N., Sachs D. H. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J. Immunol. 124:1980;533-540.
33. Padlan E. A. Anatomy of the antibody molecule. Mol. Immunol. 31:1994;169-217.
34. Plaksin D., Chacko S., McPhie P., Bax A., Padlan E. A., Margulies D. H. A T cell receptor Vα domain expressed in bacteria: does it dimerize in solution? J. Exp. Med. 184:1996;1251-1258.
35. Plaksin D., Chacko S., Navaza J., Margulies D. H., Padlan E. A. The X-ray crystal structure of a Vα2. 6 Jα38 mouse T cell receptor domain at 2.5 Å resolution: alternate modes of dimerization and crystal packing. J. Mol. Biol. 289:1999;1153-1161.
36. Reiter Y., Pastan I. Fv fragments of antibodies as novel reagents for cancer therapy and diagnosis. Trends Biotechnol. 16:1998;513-520.
37. Reiter Y., Brinkmann U., Lee B. K., Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments. Nature Biotechnol. 14:1996;1239-1245.
38. Schmidt T. G. M., Skerra A. The random peptide library-assisted engineering of a C-terminal affinity peptide, useful for the detection and purification of a functional Ig Fv fragment. Protein Eng. 6:1993;109-122.
39. Schuck P. Sedimentation analysis of noninteracting and self-association solutes using numerical solutions to the Lamm equation. Biophys. J. 75:1998;1503-1512.
40. Sheriff S., Constantine K. L. Redefining the minimal antigen-binding fragment. Nature Struct. Biol. 3:1996;733-736.
41. Tsumoto K., Niswhimiya Y., Kasai N., Ueda H., Nagamune T., Ogasahara K., Yutani K., Tokuhisa K., Matsushima M., Kumagai I. Novel selection method for engineered antibodies using the mechanism of Fv fragment stabilization in the presence of antigen. Protein Eng. 11:1997;1311-1318.
42. Ueda H., Tsumoto K., Kubota K., Suzuki E., Nagamune T., Nishimura H., Schueler P. A., Winter G., Kumagai I., Mahoney W. C. Open sandwich ELISA- a novel immunoassay based on the interchain interaction of antibody variable region. Nature Biotechnol. 14:1996;1714-1720.
43. Vitetta E. S., Thorpe P. E., Uhr J. Immunotoxins: magic bullets or misguided missiles. Trends Pharmacol. Sci. 14:1993;148-154.
44. Ward E. S. Secretion of T cell receptor fragments from recombinant Eschericia coli cells. J. Mol. Biol. 224:1992;885-890.
45. Ward E. S., Gussow D., Griffith A. D., Jones P. T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Eschericia coli. Nature. 341:1989;544-546.
46. Webster D. M., Henry A. H., Rees A. R. Antibody-antigen interactions. Curr. Opin. Struct. Biol. 4:1994;123-129.
47. Winter G., Griffith A. D., Hawkins R. E., Hoogenboom H. R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:1994;433-455.
48. Yokota T., Milenic D. E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408.